The PRISMA study flowchart. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FEV1/FVC. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for clinical efficacy. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for FEV1. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

The excluded and included studies were listed. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for PaCO₂. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Forest plot for PaO₂. by Xuqin Du (8803772)

“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO₂ (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO₂ (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”

Robust chain-length specific elevations in some intermediate chain and long chain PE phospholipids in peroxisomal mutant brain. by Michael F. Wangler (21526595)

“…</b> Levels in mol% of PE 34:4 in <i>pex2</i> and <i>pex16</i> mutant brains show significant decreases in <i>pex</i> mutant brains. For PE 34:4 in <i>pex2</i>² brain and <i>pex2</i>^<i>1</i> brain, levels are increased compared to controls (ratio 1.285, 1.202 respectively, p=0.001, p=0.005 respectively) and <i>pex2</i>^<i>2</i> brain compared to rescue (ratio 1.151, p=0.002). …”

Effect of session on winning model parameters for set size = 2 and set size = 4 for both male and females. by Juliana Chase (20469427)

“…Use of one-back strategy parameters changed significantly across sessions for male mice with (C) S1 “Inappropriate Lose Shift” decreasing across sessions, <i>p</i> = 0.01 (D) S2 = S4 “Stimulus Insensitive Win Stay” increasing, <i>p</i> = 0.009 and (E) S3 “Inappropriate Lose Stay” decreasing, <i>p</i> < 0.0001. …”

Results for the EPIC bowel subscale and the EORTC QLQ PR25 bowel symptoms scale. by John N. Staffurth (20636565)

“…</b> The results are presented on a scale of 0 (= Extremely Poor QoL) to 100 (= Extremely Good QoL). A statistically significant (6 months versus baseline, P = 0.005; 12 months versus baseline, P = 0.013) increase occurs in bowel QoL (i.e., a reduction in symptoms). …”

Strategy parameters across development for male mice in set size = 2 and set size = 4 from winning computational model. by Juliana Chase (20469427)

“…However, strategy parameter, S2 = S4 “Stimulus Insensitive Win Stay,” increased significantly for male mice in both set size = 2 (D:<i>p</i> < 0.0001) and set size = 4 (I: <i>p</i> = 0.03).…”

Shape rescue in the midface phenotype in the Dp(16)1Yey/ <i>Ripply3</i>^<i>tm1b</i> compound mutant. by José Tomás Ahumada Saavedra (22290934)

“…In light blue, the structures with no significant changes. On the left, the histogram of every point distance evaluated (in this case, more than 1.238.684 points) and the surface differences with the color code for the increase-decrease dimensions (Red to green).…”

Interannual variations. by John P. Ryan (7388621)

“…Solid black triangles along the bottom indicate significant increase (years 3,4) or decrease (year 5) in daily unique humpback whale IDs relative to the previous year (p < 0.05; one-sided Wilcoxon rank sum tests). …”

Experimental Investigation of Hydrodynamic Characteristics in Industrial Pulsed Liquid–Liquid Extraction Column by Xiucheng Yu (22634359)

“…Conversely, the droplet diameter of the organic dispersed phase decreases with increasing pulsation intensity in the pulsed sieve plate column (PSPC). …”

Heterotrophic cell growth and dry cell yield of <i>Rhodovulum sulfidophilum</i> in artificial seawater (ASW) based growth medium of different salinities, wherein 100% corresponds t... by Shamitha Rao Morey-Yagi (19779981)

Shrimp allergen extract (SAE) immunotherapy preventing the development of allergies. by Honey Dzikri Marhaeny (20480031)

ELISA kit information. by Shuailin Li (11907158)

“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”

Western blot antibody information. by Shuailin Li (11907158)

“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”

Information on healthy and aniridia subjects. by Shuailin Li (11907158)

“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”

qPCR primers information. by Shuailin Li (11907158)

“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”